Japan assesses the innovation level of medical devices by evaluating their clinical benefits, uniqueness, and improvements over existing technologies. Chuikyo and MHLW review evidence demonstrating safety, efficacy, and cost-effectiveness. Devices offering significant advancements in patient outcomes, treatment efficiency, or healthcare impact may qualify for premium pricing or new reimbursement categories under the NHI system.
